Results 41 to 50 of about 14,435 (170)
The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis
Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino +5 more
wiley +1 more source
Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications [PDF]
The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has been granted authorization or approval in several countries for the treatment of patients with mild to moderate COVID‐19 at high risk of progression to severe disease
Burger, D +47 more
core +2 more sources
Intro: Ritonavir-boosted nirmatrelvir has shown efficacy in reducing the rate of hospitalisation and 28-day mortality among unvaccinated populations with COVID-19.
S.P. Lee +8 more
doaj +1 more source
A real‐world analysis of AI chatbot performance for medicines information enquiries
Abstract Background The provision of medicines information (MI) services requires interpretation and clinical judgement of complex scenarios by pharmacists. To date, few studies have assessed the performance of artificial intelligence (AI) chatbots to assist pharmacists providing MI advice.
Duncan Yorkston +2 more
wiley +1 more source
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee +5 more
wiley +2 more sources
Background The effectiveness of nirmatrelvir–ritonavir has mainly been shown in non-hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19).
Xiaobo Han +24 more
doaj +1 more source
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao +17 more
doaj +1 more source
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo +5 more
wiley +1 more source
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
Background: Hemodialysis patients have a high risk of severe/critical COVID-19 and related high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with COVID-19 infection because of lack of evidence of safety.Objectives ...
Jiayue Lu +17 more
doaj +1 more source
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source

